The Rockefeller University

Aaron Diamond Aids Research Center

Academia Sinica

Cornell University

Columbia University

New York University

The City University of New York

Yaoxing Huang

David D Ho

Jian Yu

Chi-Huey Wong

Alice L Yu

Ming Wei Chen

Ting-Jen Rachel Cheng

Moriya Tsuji

David Joon Ho

Richard W Franck

Ruijiang Song

Craig Stuart Pace

Xin Yao

David F Gardiner

Qing Fang

Rachel Tj Cheng

John Schmieg

In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.

Bispecific HIV-1-neutralizing antibodies

Provided are tri-specific fusion antibodies created to target multiple epitopes of the Human Immunodeficiency Virus (HIV). The fusion antibodies provide improved potency and breadth against HIV as compared to monospecific and bispecific antibodies, and additionally provide a high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.

Tri-specific antibodies for HIV therapy

Bispecific HIV-1 neutralizing antibodies

In one aspect, the invention provides a DNA molecule. The DNA molecule includes a nucleotide sequence that encodes the receptor-binding domain oftoxin A or toxin B in which at least about 10% of the in-frame codons for each amino acid residue has a higher percentage use in the human genome than the corresponding in-frame codons oftoxin A or toxin B having a known sequence. Methods for generating antibodies totoxin A or toxin B, methods for reducing the risk of ainfection, and methods for treating aare also provided.

[object Object]

Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.

Fusion antibodies for HIV therapy

This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection.

Flu vaccines and methods of use thereof

The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes a synthetic glycolipid compound of Formula I, as described herein. According to the present invention, the use of a compound of Formula I as an adjuvant is attributed at least in part to the enhancement and/or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses. The methods and compositions of the present invention can be useful for prophylaxis and treatment of various infectious and neoplastic diseases.

Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases

Growing community of inventors

Brooklyn, NY, United States of America

Yaoxing Huang